Cargando…

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer

SIMPLE SUMMARY: Castration-resistant prostate cancer (CRPC) treatments include next-generation anti-androgen therapies (NGATs), taxane therapy, and PARP inhibitors (PARPi). However, resistance often occurs across and within therapeutic classes, which can complicate sequential treatment options. We d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaaf, Zachary A., Ning, Shu, Leslie, Amy R., Sharifi, Masuda, Han, Xianrui, Armstrong, Cameron, Lou, Wei, Lombard, Alan P., Liu, Chengfei, Gao, Allen C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650051/ https://www.ncbi.nlm.nih.gov/pubmed/37958444 http://dx.doi.org/10.3390/cancers15215273

Ejemplares similares

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling
por: Liu, Chengfei, et al.
Publicado: (2021)

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer()
por: Lombard, Alan P, et al.
Publicado: (2019)

Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes
por: Ning, Shu, et al.
Publicado: (2022)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2018)

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
por: Armstrong, Cameron M., et al.
Publicado: (2016)

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model
por: Qu, Sifeng, et al.
Publicado: (2013)

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
por: Xu, Pengfei, et al.
Publicado: (2023)

Profiling Prostate Cancer Therapeutic Resistance
por: Wade, Cameron A., et al.
Publicado: (2018)

Advances in landscape and related therapeutic targets of the prostate tumor microenvironment: Therapeutic targets of the prostate tumor microenvironment
por: Li, Duocai, et al.
Publicado: (2023)

Recent advances and future perspectives in the therapeutics of prostate cancer
por: Varaprasad, Ganji Lakshmi, et al.
Publicado: (2023)

Introducing Therapeutic Advances in Ophthalmology
por: Cameron, D. Joshua
Publicado: (2018)

The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer
por: Costello, Leslie C
Publicado: (2019)

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
por: Ryan, Matthew J., et al.
Publicado: (2019)

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
por: Bitting, Rhonda L., et al.
Publicado: (2011)

Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2021)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2021)

Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
por: Kahn, Barbara, et al.
Publicado: (2014)

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
por: Wadosky, Kristine M, et al.
Publicado: (2016)

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer
por: Lin, Hui-Ming, et al.
Publicado: (2018)

Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer
por: Adorno Febles, Victor R., et al.
Publicado: (2020)

Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer
por: Barquilha, Caroline N., et al.
Publicado: (2020)

Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Naseer, Faiza, et al.
Publicado: (2021)

Current strategies for targeting the activity of androgen receptor variants
por: Armstrong, Cameron M., et al.
Publicado: (2019)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021)

CNV analysis of Meishan pig by next-generation sequencing and effects of AHR gene CNV on pig reproductive traits
por: Zheng, Xianrui, et al.
Publicado: (2020)

HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER
por: Antunac, Katarina, et al.
Publicado: (2022)

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis
por: Guo, Xinjing, et al.
Publicado: (2022)

Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers
por: Laderach, Diego J., et al.
Publicado: (2013)

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
por: Wedel, S A, et al.
Publicado: (2008)

Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
por: Ulm, Michael, et al.
Publicado: (2019)

Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance
por: Saldana, Carolina, et al.
Publicado: (2021)

Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer
por: McSweeney, Sean, et al.
Publicado: (2022)

Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
por: Mirzaei, Sepideh, et al.
Publicado: (2022)

Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis
por: Hawula, Zachary J., et al.
Publicado: (2019)

Androgen Receptor Variant–Driven Prostate Cancer II: Advances in Laboratory Investigations
por: Lu, Changxue, et al.
Publicado: (2020)

Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis
por: Aghajanyan, Ivan Gerasimovich, et al.
Publicado: (2016)

Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting
por: Bisht, Shweta, et al.
Publicado: (2022)

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
por: Rajan, Prabhakar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sakio89684lset7q8nr6o0vp88